A Phase 3 interventional study of Efgartigimod IV in Generalized Myasthenia Gravis, MG - Myasthenia Gravis and gMG, sponsored by argenx. Completed at 39 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 7th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 65+
argenx · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
Clinique Neuro-Outaouais · Sites in Canada
Ages 18–80
By country, each count listing its studies:
efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2016; this study’s year is marked. 4 started in 2021.
This study's enrollment of 69 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 55 across the 20 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 8 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
18 studies in Myasthenia Gravis by argenx: 9 open now, 12 under way, 5 of them phase 3. Of 6 finished, 6 (100%) have results posted.
Among the 18 studies in Myasthenia Gravis by argenx, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 7th registered.
argenx’s Myasthenia Gravis studies by the year they started, since 2016.
7 of the studies testing efgartigimod alfa in Myasthenia Gravis that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06765161Phase 3Clinique Neuro-OutaouaisEfgartigimod in IVIG Dependent Myasthenia Gravis Patients | 2027-01-06 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06221501Shanghai Zhongshan HospitalPerioperative Efgartigimod for Thymoma and Myasthenia Gravis | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among argenx’s 18 in Myasthenia Gravis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG).
Participants will receive efgartigimod throughout the study. The participants will be randomized to the continuous regimen arm or to the cyclic regimen arm. The study consists of a part A (regimen comparison period) where participants will continue the treatment based on the treatment regimen arm they were assigned at randomization. Following part A, participants will enter part B (extension period) where all participants will receive efgartigimod in the continuous regimen. The study duration for participants is up to 138 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of the following prior or concomitant therapies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving efgartigimod IV on a continuous regimen
Biological: Efgartigimod IV
Participants receiving efgartigimod IV on a cyclic regimen
Biological: Efgartigimod IV
Intravenous infusions of efgartigimod
Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Time frame: Up to 21 weeks
Incidence of AEs, SAEs and AESIs
AE : adverse event; SAE: serious adverse event; AESI: adverse event of special interest
Time frame: Up to 135 weeks
Change From Baseline in the MG-ADL Total Score Over Time
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Time frame: Up to 126 weeks
Normalized Area Under the Effect Curve (AUEC) of MG-ADL Total Score Improvement From Baseline
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Time frame: Up to 21 weeks
Characterization of MG-ADL Total Score Change From Baseline
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Time frame: Up to 21 weeks
Percentage of Participants Who Have a ≥ 2, 3, 4, or 5 Points Improvement in MG-ADL Total Score From Baseline
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Time frame: Up to 21 weeks
Percentage of Time Participants Have a Change in MG-ADL Total Score of at Least 2 Points From Baseline During Week 4 Through Week 21
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Time frame: From week 4 to week 21
Percentage of Participants Who Achieve MSE, Defined as a MG-ADL Total Score of 0 or 1
MSE = minimal symptom expression; The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Time frame: Up to 21 weeks
The study was conducted at 31 sites that enrolled participants with anti-acetylcholine receptor antibody (AChR-Ab) seropositive gMG in 11 countries. A total of 98 participants were screened of whom 69 were randomized and treated. The results presented are based on the primary completion date. Remaining results will be reported within a year of global study completion.
| Milestone | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen |
|---|---|---|
| Started | 17 | 52 |
| Completed part a | 15 | 50 |
| Completed | 11 | 35 |
| Not completed | 6 | 17 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Requires prohibited medication | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Other reasons | 0 | 2 |
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
| Score on a scale | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen |
|---|---|---|
| Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm | -5.13 (-6.499 to -3.767) | -4.61 (-5.383 to -3.845) |
AE : adverse event; SAE: serious adverse event; AESI: adverse event of special interest
Results for this outcome have not been posted.
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Results for this outcome have not been posted.
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Results for this outcome have not been posted.
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Results for this outcome have not been posted.
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Results for this outcome have not been posted.
The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Results for this outcome have not been posted.
MSE = minimal symptom expression; The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.
Results for this outcome have not been posted.
Collected over Part A, up to week 21. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod IV - Cyclic Regimen | 0/17 (0%) | 1/17 (5.9%) | 16/17 (94.1%) |
| Efgartigimod IV - Continuous Regimen | 0/52 (0%) | 7/52 (13.5%) | 43/52 (82.7%) |
| Event | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen |
|---|---|---|
| COVID-19Infections and infestations | 1/17 | 0/52 |
| MYASTHENIA GRAVISNervous system disorders | 1/17 | 2/52 |
| MYASTHENIA GRAVIS CRISISNervous system disorders | 1/17 | 0/52 |
| BRONCHITISInfections and infestations | 0/17 | 1/52 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/17 | 1/52 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/17 | 1/52 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/17 | 1/52 |
| RESPIRATORY SYNCYTIAL VIRUSInfections and infestations | 0/17 | 1/52 |
| Event | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen |
|---|---|---|
| HEADACHENervous system disorders | 5/17 | 8/52 |
| COVID-19Infections and infestations | 1/17 | 11/52 |
| INFLUENZAInfections and infestations | 2/17 | 3/52 |
| NASOPHARYNGITISInfections and infestations | 2/17 | 1/52 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/17 | 5/52 |
| HYPERCHOLESTEROLAEMIAMetabolism and nutrition disorders | 2/17 | 2/52 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 2/17 | 1/52 |
| MYALGIAMusculoskeletal and connective tissue disorders | 2/17 | 2/52 |
| DIZZINESSNervous system disorders | 2/17 | 1/52 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 2/17 | 0/52 |
| Age, Continuous(Age (years)) | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen | Total |
|---|---|---|---|
| Mean | 52.4 ± 16.10 | 57.1 ± 16.49 | 55.9 ± 16.40 |
| Age, Customized(Participants) | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen | Total |
|---|---|---|---|
| Age, category — 18 - 64 years | 12 | 32 | 44 |
| Age, category — >= 65 years | 5 | 20 | 25 |
| Sex: Female, Male(Participants) | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen | Total |
|---|---|---|---|
| Female | 9 | 34 | 43 |
| Male | 8 | 18 | 26 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen | Total |
|---|---|---|---|
| Race — Asian | 0 | 1 | 1 |
| Race — Black or African American | 2 | 0 | 2 |
| Race — White | 14 | 50 | 64 |
| Race — Other | 1 | 0 | 1 |
| Race — Unknown | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod IV - Cyclic Regimen | Efgartigimod IV - Continuous Regimen | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 2 | 2 |
| Ethnicity — Not Hispanic or Latino | 17 | 50 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2021 to primary completion in Aug 2023, 20 months.
Results were first posted in May 2026, 2 years 9 months after primary completion. A results delay was requested in Feb 2024.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 20 months is below that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa